Skip to content
10-Q

Quarterly Report

REGENEREX PHARMA, INC. RGPX

0001472375-24-000005

← back to feed
Filed
Feb 5, 2024 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q3 2023 · Feb 5, 2024 278M sh
Cash And Equivalents Q3 2023 · Dec 31, 2023 $7.86K
Cash And Equivalents Q3 2023 · Mar 31, 2023 $1.14K
Current Liabilities Q3 2023 · Dec 31, 2023 $3.56M
Current Liabilities Q3 2023 · Mar 31, 2023 $776.78K
Total Liabilities Q3 2023 · Dec 31, 2023 $4.73M
Total Liabilities Q3 2023 · Mar 31, 2023 $1.13M
Current Assets Q3 2023 · Dec 31, 2023 $9.28K
Current Assets Q3 2023 · Mar 31, 2023 $1.14K
Total Assets Q3 2023 · Dec 31, 2023 $852.14K
Total Assets Q3 2023 · Mar 31, 2023 $6.54K
Operating Cash Flow Q3 2023 · Dec 31, 2022 −$73.14K
Stockholders Equity Q3 2023 · Dec 31, 2022 −$1.08M
Stockholders Equity Q3 2023 · Sep 30, 2022 −$1.03M
Stockholders Equity Q3 2023 · Mar 31, 2022 −$985.62K
Net Income Q3 2023 · Dec 31, 2022 −$49.4K
Net Income Q3 2023 · Dec 31, 2022 −$91.04K
Net Income Q3 2023 · Sep 30, 2022 −$41.64K
Operating Income Q3 2023 · Dec 31, 2022 −$29.1K
Operating Income Q3 2023 · Dec 31, 2022 −$67.89K